Thu, Oct 23, 2014, 11:16 AM EDT - U.S. Markets close in 4 hrs 44 mins

Recent

% | $
Quotes you view appear here for quick access.

Accentia Biopharmaceuticals, Inc. Message Board

  • luvboats2003 luvboats2003 Apr 11, 2013 10:51 AM Flag

    Doc added to private Yahoo group

    Anyone care to comment on this disturbing news?

    The Equity Committee in the Biovest Chapter 11 case recently filed the attached "Motion to Appoint an Examiner or Chapter 11 Trustee." According to the Motion, "recent information has been uncovered demonstrating that the Debtor has, since 2005, consistently misrepresented to the public the status of its efforts to obtain FDA approval for its principal drug" (page 1).

    The Equity Committee argues that "the Court shall order the appointment of a trustee
    'for cause, including fraud, dishonesty, incompetence, or gross mismanagement of the affairs of
    the debtor by current management' …."

    According to the EC: "In just the very brief discovery
    taken in connection with the DIP financing, the Committee discovered evidence that the Debtor
    mishandled the process for FDA approval and misrepresented the status of the process to the
    public. Despite the Debtor expressing publicly its surprise in 2012 at not receiving FDA
    approval of its Phase 3 study for BiovaxID, FDA meeting minutes detail how FDA, beginning in
    2005, informed the Debtor repeatedly that the "design, conduct, and statistical analysis" of its
    Phase 3 study were deficient. FDA informed Biovest in 2008 and 2010 that its Phase 3 study
    was "on its face scientifically incomplete to establish clinical evidence of effectiveness."
    Biovest failed to inform the public about its meetings with, and communications from, FDA in
    2005, 2008, and 2010.

    "Nor did Biovest inform the public about FDA's findings during those years of (a) the inadequacy of the Phase 3 data for demonstrating safety and efficacy of BiovaxID, and (b)
    the impropriety of Biovest's statistical analysis of that data. On the contrary, Biovest led the
    public to believe (a) that Biovest had not presented its Phase 3 data to FDA until 2012, and (b)
    that the data, and Biovest's statistical analysis of the data, could be acceptable to FDA. In fact,
    however, FDA had repeatedly told Biovest

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • luv, I was swooping down to find the same-ole-same-ole -- last thing expected was the contents of your post. first of all, thank you -- I cannot pretend not to be stunned...I've been fighting off a gnawing disdain towards these medical doctors running the company, but hey, I know people who can ply both trades....but this is beyond incompetency!! this is about irresponsible ego run rampant, superceding the good of everything -- the company, the shareholders, the FDA, and last but not least, the very patients this drug was supposed to help! The damage done is deep here...I always look to litigation as the last resort -- kind of like surgery -- let's start out with the least unobtrusive alternatives....but THIS is exactly what litigation is meant to target -- criminal behavior. I am outraged and hope people here familiar with legal process speak out!

    • We are doing the best for the shareholders.....yeah for sure.Well i hope that they will end up in jail.Then we should motivate some of their inmates to do the best for them all day and all night long.

    • Guess we find out on the 18th when they're due in court

 
ABPI
0.0054+0.0009(+20.00%)10:50 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.